NEWS

Cerus Endovascular Successfully Completes Series B Financing and Receive...

FREMONT, Calif. and OXFORD, England, Feb. 21, 2020 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has now successfully completed its Series B financing having raised a total of $19.0 million from current and new institutional investors since commencement of the round in July 2018. The company also reported that it has received approval from the U.S. Food and Drug Administration (FDA) for its first microcatheter. Commercial sales are expected to begin during the second quarter of 2020.

Cerus Endovascular Receives CE Mark Approval for its Contour Neurovascul...

FREMONT, Calif. and OXFORD, England - Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced that it has received CE Mark approval for its lead product, the Contour Neurovascular System™, for the treatment of intracranial aneurysms.

Cascade Net – an innovative non-occlusive remodeling device for temporar...

Multi-center clinical experience in 15 cases with the innovative CE-marked Cascade Net device was highlighted in the January 2020 Journal of Neurosurgery article, “Early experience with a novel net temporary bridging device (Cascade) to assist endovascular coil embolization of intracranial aneurysms” by Dr Alejandro Tomasello et al*.

Sensome raises $9 million B round with equity investment from Asahi Intecc

The two companies start development program to integrate Sensome’s tissue micro-sensor into Asahi’s world class guidewire

MicroVention Announces FDA Premarket Approval of a New Flow Diverter for...

Aliso Viejo, CA. – January 9, 2020 – MicroVention, Inc., a U.S. based subsidiary of Terumo and a global neurovascular company announced the FDA Premarket Approval (PMA) for the FRED® (Flow Re-Direction Endoluminal Device) device for the treatment of brain aneurysms.  

Medtronic Receives CE Mark Approval for the Percept™ PC Neurostimulator...

This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients 

Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stim...

Randomized Control Trial Results to be Presented at NANS Jan. 23-26 in Las Vegas; New, Proprietary Differential Target Multiplexed (DTM) Therapy Available on Medtronic Intellis Spinal Cord Stimulation Platform

Philips announces WE-TRUST multicenter clinical trial to assess impact o...

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major clinical trial to assess the impact of a ‘Direct to Angio Suite’ workflow on stroke patient outcomes.

Perflow Medical Receives CE Mark Approval of Novel Cascade™ Agile

Promising clinical data for Cascade Net published in the Journal of NeuroInterventional Surgery

Sim&Cure Announces U.S. FDA 510(k) Clearance for Sim&Size software

Montpellier – Sim&Cure is honored and proud to announce last September 17, Sim&Size® obtained U.S.Food and Drug Administration (FDA) 510(k) clearance.